Abstract: An atomic layer etching method using a ligand exchange reaction may include a substrate providing step of putting a substrate with a thin film formed thereon into a reaction chamber, a halogenated thin film forming step of forming a halogenated thin film on a surface of the thin film by infusing a halogenated gas into the reaction chamber, and an etching step of etching the halogenated thin film by infusing a ligand without a metal or metal precursor into the reaction chamber with the substrate with the halogenated thin film.
Type:
Grant
Filed:
January 17, 2023
Date of Patent:
March 18, 2025
Assignees:
SK hynix Inc., Merck Patent GmbH
Inventors:
Jae Chul Lee, Hyun Sik Noh, Dong Kyun Lee, Eun Ae Jung, Kyoung-Mun Kim, Jooyong Kim, Younghun Byun, Byeong Il Yang, Changhyun Jin
Abstract: The invention relates to substituted heterocycles of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
Type:
Application
Filed:
January 9, 2023
Publication date:
March 13, 2025
Applicants:
MERCK PATENT GMBH, THE INSTITUTE OF CANCER RESEARCH, CANCER RESEARCH HORIZONS
Inventors:
Hans-Peter BUCHSTALLER, Daniel KUHN, Ian COLLINS, Thomas MATTHEWS, Jan LANZ, John CALDWELL, Giampiero COLOMBANO
Abstract: The present invention provides a method for multiproduct resin reuse (MRR) utilizing ionic exchange chromatography columns. The methods of the invention outline the cleaning steps necessary for reuse as well as the analytical processes used in determining product carryover from production of one product to the next. The invention outlines a successful MRR strategy that can be utilized not just in lab-scale studies, but in a GMP manufacturing setting.
Type:
Application
Filed:
August 9, 2024
Publication date:
March 13, 2025
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Collette M. Cutler, Hong Li, Ren Liu, Jeffrey T. McPhee, Douglas Dennis Richardson, II, Patricia A. Rose, Patricia Rowicki
Abstract: A liquid crystal device for absorbing and/or scattering a controllable amount of traversing light comprises an active layer having a first viewport surface, a second viewport surface, and at least two side surfaces. The first and second viewport surfaces contact respective first and second planar electrodes. The first and second planar electrodes respectively comprise first and second supply areas for receiving a control voltage for controlling the active layer. A first supply contacting device electrically connects to the first supply area, and a second supply contacting device electrically connects to the second supply area. The supply areas and the supply contacting devices each associate to one or more side surfaces, arranged to extend along at least a part of their respective associated sides, wherein the first supply contacting device and the second supply contacting device associate to adjacent side surfaces.
Type:
Application
Filed:
September 12, 2024
Publication date:
March 13, 2025
Applicant:
MERCK PATENT GmbH
Inventors:
Ties DE JONG, Florian DHALLUIN, Chuan NIE, Muhammad ALI
Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
Type:
Application
Filed:
November 26, 2024
Publication date:
March 13, 2025
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Ashok Arasappan, Ian M. Bell, Michael J. Breslin, Christopher James Bungard, Christopher S. Burgey, Harry R. Chobanian, Jason M. Cox, Anthony T. Ginnetti, Deodial Guy Guiadeen, Kristen L.G. Jones, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
Abstract: The present invention relates to compounds of formula (I), to processes for producing the compounds, and to electronic devices containing at least one compound of formula (I).
Type:
Grant
Filed:
November 28, 2019
Date of Patent:
March 11, 2025
Assignee:
Merck Patent GmbH
Inventors:
Amir Parham, Jonas Kroeber, Jens Engelhart, Anja Jatsch, Christian Eickhoff, Christian Ehrenreich, Jens Kaiser
Abstract: Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same.
Type:
Grant
Filed:
December 2, 2019
Date of Patent:
March 11, 2025
Assignee:
Merck Sharp & Dohme LLC
Inventors:
Christopher J. Bungard, Helen Y. Chen, Jason M. Cox, Liangqin Guo, Michael J. Kelly, III, Ronald M. Kim, Mark E. Layton, Hong Liu, Jian Liu, Mehul F. Patel, James J. Perkins, Deping Wang, Walter Won, Younong Yu, Ting Zhang
Abstract: The present invention is directed to cyclobutyl pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Type:
Grant
Filed:
December 6, 2019
Date of Patent:
March 11, 2025
Assignee:
Merck Sharp & Dohme LLC
Inventors:
Ashok Arasappan, Jason M. Cox, John S. Debenham, Zhuyan Guo, Zhong Lai, Dongfang Meng
Abstract: The invention relates to stable formulations comprising antibodies or antigen binding fragments thereof that bind to cytotoxic T lymphocyte associated antigen 4 (CTLA4), optionally further containing an anti-human programmed death receptor 1 (PD-1) antibody or antigen binding fragment thereof. Also provided are methods of treating various cancers and chronic infections with the formulations of the invention.
Type:
Application
Filed:
September 11, 2024
Publication date:
March 6, 2025
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Soumendu Bhattacharya, Chakravarthy Nachu Narasimhan, Manoj K. Sharma, Xiaoyu Yang, Arnab De, Rubi Burlage, Jason K. Cheung
Abstract: The invention relates to a liquid-crystalline medium, in particular based on a mixture of polar compounds, and to the use thereof for an active-matrix display, in particular based on the VA, SA-VA, IPS, PS-IPS, FFS, PS-FFS, UB-FFS or PS-UB-FFS effect.
Abstract: The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula I or a pharmaceutically acceptable salt or co-crystal thereof, wherein X is —F or —Cl, less frequently than once daily.
Type:
Application
Filed:
November 13, 2024
Publication date:
March 6, 2025
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Daria Hazuda, Michael D. Miller, Jay A. Grobler, Deborah Anne Nicoll-Griffith
Abstract: A process for the production of flake-form, crystalline particles having an aurivillius structure, the use thereof as effect pigments or as substrates of effect pigments, furthermore, effect pigments which contain coated or uncoated flake-form, crystalline particles having an aurivillius structure as substrates, and the use thereof in various products.
Type:
Application
Filed:
April 28, 2022
Publication date:
March 6, 2025
Applicant:
Merck Patent GmbH
Inventors:
Christoph Schmidt, Carsten Handrosch, Tanja Delp, Andrea Heyland, Johann Bauer
Abstract: The invention relates to methods for treating cancer in a patient comprising subcutaneously administering a PD-1 antagonist, e.g., an anti-PD-1 antibody, or antigen binding fragment thereof, (e.g. pembrolizumab), in specific amounts to the patient. In some embodiments, the administration occurs about every three weeks. In some embodiments, the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 280 mg to about 450 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits formulated for subcutaneous administration comprising a dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.
Type:
Application
Filed:
April 4, 2022
Publication date:
March 6, 2025
Applicant:
MERCK SHARP & DOHME LLC
Inventors:
Mallika LALA, Carolina DE MIRANDA SILVA, Ferdous GHEYAS, Yogita KRISHNAMACHARI, Elliot Keith CHARTASH, Lokesh JAIN, Venkata Naga Ratna Pavan Kumar VADDADY
Abstract: Described herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.
Type:
Grant
Filed:
December 13, 2019
Date of Patent:
March 4, 2025
Assignee:
Merck Sharp & Dohme LLC
Inventors:
Abdelghani Abe Achab, Matthew L. Childers, Jared N. Cumming, Symon Gathiaka, Charles A. Lesburg, Derun Li, Min Lu, Matthew J. Mitcheltree, Anandan Palani, Rachel L. Palte, Hongjun Zhang
Abstract: Compounds of formula I liquid crystal media containing these compounds, and high-frequency components containing these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas, phased array antennas, and devices containing these components, and furthermore optical components containing these liquid-crystalline media, operable in the infrared region of the electromagnetic spectrum.
Abstract: To provide a method for manufacturing a cured film having high film density, high film hardness and high etching resistance. A method for manufacturing a cured film comprising (1) applying a composition (i) above a substrate; (2) forming a hydro-carbon-containing film from the composition (i); and (3) irradiating the hydrocarbon-containing film with plasma, electron beam and/or ion to form a cured film. Use of the cured film.
Abstract: The present disclosure is directed to compounds of Formula I: and their use as anti-viral agents for inhibition of the replication of hRSV and hMPV and treatment and prophylaxis of hRSV and hMPV infection.
Type:
Application
Filed:
August 15, 2024
Publication date:
February 27, 2025
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Brett R. Ambler, Douglas C. Beshore, Christopher James Bungard, Weizhe Dong, Danielle M. Hurzy, Peter J. Manley, Vanessa L. Rada, II, Kelly-Ann S. Schlegel, Linda M. Suen-Lai, Mahdieh Yazdani
Abstract: The present invention provides lyophilized pellets of low concentrations of antibodies in the form of lyospheres. These lyospheres provide pre-measured antibody concentrations suitable for diagnostic and quality control assays.
Type:
Application
Filed:
November 13, 2024
Publication date:
February 27, 2025
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Akhilesh Bhambhani, Thorsten Verch, Morrisa C. Jones, Mary Retzlaff, Jessica R. Sinacola, Silikhone L. Bouaraphan
Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
Type:
Application
Filed:
August 5, 2024
Publication date:
February 27, 2025
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Sybil M. G. Williams, Drake LaFace, Laurence Fayadat-Dilman, Gopalan Raghunathan, Linda Liang, Wolfgang Seghezzi
Abstract: A liquid crystal display (LCD) of the chiral polymer stabilized alignment (C-PSA) mode, a method of its production and its use as an energy-saving display.
Type:
Application
Filed:
December 14, 2022
Publication date:
February 27, 2025
Applicant:
MERCK PATENT GmbH
Inventors:
Chia-Sheng HSIEH, Yinghua HUANG, Cheng-Jui LIN